Diabetes und kardiovaskuläre Erkrankungen, Zusammenfassung der ESC-Leitlinien 2013

Abstract

Patients with Diabetes mellitus have an increased risk for micro- and macrovascular complications. Diabetes therapy should therefore aim for the prevention of cardiovascular disease. This can be reached by a combination of life style modification in addition to optimal medical therapy of blood pressure, -lipids and blood glucose. The therapeutic approach to coronary artery disease, heart failure or arrhythmias does not differ in patients with diabetes from the general population. Yet, if a coronary revascularization therapy is needed, patients with diabetes and complex multi-vessel disease do benefit from aortocoronary bypass operation rather than an interventional approach. Percutaneous coronary intervention in diabetic patients should be performed primarily with drug-eluting stents rather than bare metal stents. Screening for microangiopathic complications including retinopathy, nephropathy or neuropathy is advised on a regular basis.

• Literatur

• 1 DECODE Study Group. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts.. Diabetes Care 2003; 26: 61-69
• 2 Kengne AP. Special report from the 2011 International Diabetes Federation. Cardiovasc J Afr 2012; 23: 51-53
• 3 Diagnosis and classification of diabetes mellitus. Diabetes Care 2012; 35: 64-71
• 4 Genuth S, Alberti KG, Bennett P et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-3167
• 5 Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 2003; 26: 725-731
• 6 Ning F, Tuomilehto J, Pyorala K et al. Cardiovascular disease mortality in Europeans in relation to fasting and 2-h plasma glucose levels within a normoglycemic range. Diabetes Care 2010; 33: 2211-2216
• 7 Meigs JB, Nathan DM, D'Agostino RB et al. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002; 25: 1845-1850
• 8 Mann JI, De Leeuw I, Hermansen K et al. Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus. Nutr Metab Cardiovasc Dis 2004; 14: 373-394
• 9 Burr JF, Rowan CP, Jamnik VK et al. The role of physical activity in type 2 diabetes prevention: physiological and practical perspectives. Phys Sportsmed 2010; 38: 72-82
• 10 Lindstrom J, Neumann A, Sheppard KE et al. Take action to prevent diabetes – the IMAGE toolkit for the prevention of type 2 diabetes in Europe. Horm Metab Res 2010; 42: 37-55
• 11 Wannamethee SG, Papacosta O, Lawlor DA et al. Do women exhibit greater differences in established and novel risk factors between diabetes and non-diabetes than men? The British Regional Heart Study and British Women's Heart Health Study. Diabetologia 2012; 55: 80-87
• 12 Gerstein HC, Mann JF, Yi Q et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426
• 13 Valensi P, Lorgis L, Cottin Y. Prevalence, incidence, predictive factors and prognosis of silent myocardial infarction: a review of the literature. Arch Cardiovasc Dis 2011; 104: 178-188
• 14 Young LH, Wackers FJ, Chyun DA et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA 2009; 301: 1547-1555
• 15 Estruch R, Ros E, Salas-Salvado J et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013; 368: 1279-1290
• 16 Sacks FM, Bray GA, Carey VJ et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009; 360: 859-873
• 17 Snowling NJ, Hopkins WG. Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta-analysis. Diabetes Care 2006; 29: 2518-2527
• 18 The Diabetes Control and Complications Trial Research Group.. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986
• 19 UK Prospective Diabetes Study (UKPDS) Group.. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).. Lancet 1998; 352: 837-853
• 20 Turnbull FM, Abraira C, Anderson RJ et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288-2298
• 21 Cushman WC, Evans GW, Byington RP et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575-1585
• 22 Ferroni P, Basili S, Falco A et al. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004; 2: 1282-1291
• 23 Pignone M, Alberts MJ, Colwell JA et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation 2010; 121: 2694-2701
• 24 Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860
• 25 Dillinger JG, Drissa A, Sideris G et al. Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. Am Heart J 2012; 164: 600-606, e601
• 26 Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015
• 27 Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057
• 28 Wiviott SD, Braunwald E, Angiolillo DJ et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction. Circulation 2008; 118: 1626-1636
• 29 Gaede P, Vedel P, Parving HH et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617-622
• 30 Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393
• 31 Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153
• 32 Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559
• 33 Kosiborod M, Inzucchi SE, Krumholz HM et al. Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. Circulation 2008; 117: 1018-1027
• 34 Kosiborod M, Inzucchi SE, Goyal A et al. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. JAMA 2009; 301: 1556-1564
• 35 Frye RL, August P, Brooks MM et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360: 2503-2515
• 36 Timmer JR, Ottervanger JP, de Boer MJ et al. Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis-2 trial. Arch Intern Med 2007; 167: 1353-1359
• 37 Hlatky MA, Boothroyd DB, Bravata DM et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet 2009; 373: 1190-1197
• 38 Serruys PW, Morice MC, Kappetein AP et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360: 961-972
• 39 Farkouh ME, Domanski M, Sleeper LA et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012; 367: 2375-2384
• 40 Sabate M, Jimenez-Quevedo P, Angiolillo DJ et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 2005; 112: 2175-2183
• 41 Mulukutla SR, Vlachos HA, Marroquin OC et al. Impact of drug-eluting stents among insulin-treated diabetic patients: a report from the National Heart, Lung, and Blood Institute Dynamic Registry. JACC Cardiovasc Interv 2008; 1: 139-147
• 42 Kengne AP, Turnbull F, MacMahon S. The Framingham Study, diabetes mellitus and cardiovascular disease: turning back the clock. Prog Cardiovasc Dis 2010; 53: 45-51
• 43 Thrainsdottir IS, Aspelund T, Thorgeirsson G et al. The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care 2005; 28: 612-616
• 44 Vermes E, Ducharme A, Bourassa MG et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 2003; 107: 1291-1296
• 45 Ryden L, Armstrong PW, Cleland JG et al. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J 2000; 21: 1967-1978
• 46 MacDonald MR, Eurich DT, Majumdar SR et al. Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. Diabetes Care 2010; 33: 1213-1218
• 47 Krahn AD, Manfreda J, Tate RB et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98: 476-484
• 48 Du X, Ninomiya T, de Galan B et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J 2009; 30: 1128-1135
• 49 Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747
• 50 Kannel WB, Wilson PW, D'Agostino RB et al. Sudden coronary death in women. Am Heart J 1998; 136: 205-212
• 51 Albert CM, Chae CU, Grodstein F et al. Prospective study of sudden cardiac death among women in the United States. Circulation 2003; 107: 2096-2101
• 52 Diehm C, Allenberg JR, Pittrow D et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation 2009; 120: 2053-2061